Slow self-activation enhances the potency of viridin prodrugs.

When the viridin wortmannin (Wm) is modified by reaction with certain nucleophiles at the C20 position, the compounds obtained exhibit an improved antiproliferative activity even though a covalent reaction between C20 and a lysine in the active site of PI3 kinase is essential to Wm's ability to inhibit this enzyme. Here we show that this improved potency results from an intramolecular attack by the C6 hydroxyl group that slowly converts these inactive prodrugs to the active species Wm over the 48 h duration of the antiproliferative assay. Our results provide a guide for selecting Wm-like compounds to maximize kinase inhibition with the variety of protocols used to assess the role of PI3 kinase in biological systems, or for achieving optimal therapeutic effects in vivo . In addition, the slow self-activation of WmC20 derivatives provides a mechanism that can be exploited to obtain kinase inhibitors endowed with physical and pharmacokinetic properties far different from man-made kinase inhibitors because they do not bind to kinase active sites.

[1]  R. Weissleder,et al.  Fate of a bioactive fluorescent wortmannin derivative in cells. , 2008, Bioconjugate chemistry.

[2]  R. Weissleder,et al.  Covalent reactions of wortmannin under physiological conditions. , 2007, Chemistry & biology.

[3]  C. Rommel,et al.  PI3Kγ inhibition: towards an 'aspirin of the 21st century'? , 2006, Nature Reviews Drug Discovery.

[4]  Ruth Duncan,et al.  Polymer conjugates as anticancer nanomedicines , 2006, Nature Reviews Cancer.

[5]  Robbie Loewith,et al.  A pharmacological map of the PI3-K family defines a role for p110 alpha in signaling: The structure of complex of phosphoinositide 3- kinase gamma with inhibitor PIK-39 , 2006 .

[6]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[7]  Hushan Yuan,et al.  Wortmannin-C20 conjugates generate wortmannin. , 2006, Journal of medicinal chemistry.

[8]  J. Skotnicki,et al.  Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models. , 2006, Journal of medicinal chemistry.

[9]  Matthias K Schwarz,et al.  PI3Kgamma inhibition: towards an 'aspirin of the 21st century'? , 2006, Nature reviews. Drug discovery.

[10]  María J Vicent,et al.  Polymer conjugates: nanosized medicines for treating cancer. , 2006, Trends in biotechnology.

[11]  T. Wandless,et al.  A Cell-permeable, Activity-based Probe for Protein and Lipid Kinases* , 2005, Journal of Biological Chemistry.

[12]  P. Wipf,et al.  Chemistry and biology of wortmannin. , 2005, Organic & biomolecular chemistry.

[13]  Ralph Weissleder,et al.  Transport Of Surface‐Modified Nanoparticles Through Cell Monolayers , 2005, Chembiochem : a European journal of chemical biology.

[14]  H. Gubler,et al.  Antiinflammatory activity of the new mould metabolite 11-desacetoxy-wortmannin and of some of its derivatives , 1974, Experientia.

[15]  D. Ferris,et al.  Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. , 2005, Chemistry & biology.

[16]  P. Wipf,et al.  Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. , 2004, Molecular cancer therapeutics.

[17]  P. Wipf,et al.  Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin. , 2004, Organic & biomolecular chemistry.

[18]  P. Finan,et al.  PI 3-kinase inhibition: a therapeutic target for respiratory disease. , 2004, Biochemical Society transactions.

[19]  C. Vlahos,et al.  Inhibitors of Cellular Signaling Targets , 2004 .

[20]  C. Vlahos,et al.  Inhibitors of cellular signaling targets: designs and limitations. , 2004, Methods in molecular biology.

[21]  E. Zuhowski,et al.  Use of high-performance liquid chromatography to characterize the rapid decomposition of wortmannin in tissue culture media. , 2003, Analytical Biochemistry.

[22]  R. Weissleder,et al.  Uptake and metabolism of a dual fluorochrome Tat-nanoparticle in HeLa cells. , 2003, Bioconjugate chemistry.

[23]  P. Finan,et al.  Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. , 2003, Current opinion in pharmacology.

[24]  Henric Olsson,et al.  Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts. , 2003, Analytical biochemistry.

[25]  P. Finan,et al.  Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy. , 2003, Biochemical Society transactions.

[26]  P. Finan,et al.  Phosphoinositide 3-Kinase γ Is an Essential Amplifier of Mast Cell Function , 2002 .

[27]  P. Finan,et al.  Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. , 2002, Immunity.

[28]  P. Finan,et al.  Phosphoinositide 3-kinase γ: a key modulator in inflammation and allergy , 2001 .

[29]  Roger L. Williams,et al.  Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.

[30]  G. Paine-Murrieta,et al.  Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase , 1999, Cancer Chemotherapy and Pharmacology.

[31]  J. Sarkaria,et al.  Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. , 1998, Cancer research.

[32]  R. Schultz,et al.  Synthesis and in vitro Evaluation of New Wortmannin Esters: Potent Inhibitors of Phosphatidylinositol 3‐Kinase. , 1997 .

[33]  R. Abraham,et al.  Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3‐kinase inhibitors, wortmannin and LY294002. , 1996, The EMBO journal.

[34]  M. Zvelebil,et al.  Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction , 1996, Molecular and cellular biology.

[35]  J. Dodge,et al.  Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. , 1996, Journal of medicinal chemistry.

[36]  M. Connelly,et al.  DNA-dependent protein kinase catalytic subunit: A relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product , 1995, Cell.

[37]  B. Norman,et al.  Synthetic studies on the furan ring of wortmannin , 1995 .

[38]  G. Powis,et al.  In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. , 1995, Anticancer research.

[39]  M. Thelen,et al.  Wortmannin binds specifically to 1-phosphatidylinositol 3-kinase while inhibiting guanine nucleotide-binding protein-coupled receptor signaling in neutrophil leukocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Dodge,et al.  Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. , 1994, Cancer research.

[41]  Y. Nonomura,et al.  Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. , 1993, The Journal of biological chemistry.

[42]  M. Baggiolini,et al.  Inhibition of the phagocytosis-induced respiratory burst by the fungal metabolite wortmannin and some analogues. , 1987, Experimental cell research.

[43]  A. Cerami,et al.  Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. , 1976, The New England journal of medicine.